share_log

This Insider Has Just Sold Shares In Atara Biotherapeutics

This Insider Has Just Sold Shares In Atara Biotherapeutics

這位知情人士剛剛出售了Atara Biotherapeutics的股份
Simply Wall St ·  05/22 08:36

We note that the Atara Biotherapeutics, Inc. (NASDAQ:ATRA) President, Pascal Touchon, recently sold US$50k worth of stock for US$0.62 per share. It might not be a huge sale, but it did reduce their holding size 12%, hardly encouraging.

我們注意到,阿塔拉生物治療公司(納斯達克股票代碼:ATRA)總裁帕斯卡爾·塔雄最近以每股0.62美元的價格出售了價值5萬美元的股票。這可能不是一筆大筆交易,但確實將他們的持股規模減少了12%,這並不令人鼓舞。

The Last 12 Months Of Insider Transactions At Atara Biotherapeutics

Atara Biotherapeutics最近12個月的內幕交易

In the last twelve months, the biggest single purchase by an insider was when Independent Director Eric Dobmeier bought US$101k worth of shares at a price of US$0.23 per share. Even though the purchase was made at a significantly lower price than the recent price (US$0.69), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

在過去的十二個月中,內部人士最大的一次收購是獨立董事埃裏克·多布邁爾以每股0.23美元的價格購買了價值10.1萬美元的股票。儘管此次收購的價格明顯低於近期價格(0.69美元),但我們仍然認爲內幕買入是積極的。由於股票是以較低的價格購買的,因此這次特殊的購買並不能告訴我們太多內部人士對當前股價的看法。

Happily, we note that in the last year insiders paid US$195k for 816.83k shares. But they sold 419.84k shares for US$341k. All up, insiders sold more shares in Atara Biotherapeutics than they bought, over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

令人高興的是,我們注意到,去年內部人士支付了19.5萬美元購買了816.83萬股股票。但他們以34.1萬美元的價格出售了419.84萬股股票。總而言之,在過去的一年中,內部人士出售的Atara Biotherapeutics股票比他們買入的還要多。你可以在下面看到過去 12 個月的內幕交易(公司和個人)的直觀描述。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!

insider-trading-volume
NasdaqGS:ATRA Insider Trading Volume May 22nd 2024
納斯達克股票代碼:ATRA 內幕交易量 2024 年 5 月 22 日

For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找隱藏寶石的人來說,這份最近有內幕收購的小盤股公司的免費清單可能就是門票。

Does Atara Biotherapeutics Boast High Insider Ownership?

Atara Biotherapeutics是否擁有較高的內部所有權?

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests Atara Biotherapeutics insiders own 1.6% of the company, worth about US$1.3m. I generally like to see higher levels of ownership.

對於普通股股東來說,值得檢查一下公司內部人士持有多少股票。較高的內部所有權通常會使公司領導層更加關注股東的利益。我們的數據顯示,Atara Biotherapeutics內部人士擁有該公司1.6%的股份,價值約130萬美元。我通常希望看到更高的所有權水平。

So What Does This Data Suggest About Atara Biotherapeutics Insiders?

那麼這些數據對Atara Biotherapeutics Insiders有何啓示呢?

Insiders haven't bought Atara Biotherapeutics stock in the last three months, but there was some selling. Despite some insider buying, the longer term picture doesn't make us feel much more positive. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we'd only buy after very careful consideration. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. When we did our research, we found 6 warning signs for Atara Biotherapeutics (1 is concerning!) that we believe deserve your full attention.

內部人士在過去三個月中沒有購買過Atara Biotherapeutics的股票,但出現了一些拋售。儘管有一些內幕買盤,但長期前景並不能使我們感到更加樂觀。內部人士擁有該公司的股票相對較少,當你考慮銷售情況時,我們對這隻股票並不特別興奮。因此,我們只有在經過仔細考慮後才會購買。因此,這些內幕交易可以幫助我們建立有關股票的論點,但也值得了解該公司面臨的風險。當我們進行研究時,我們發現了Atara Biotherapeutics的6個警告信號(其中一個令人擔憂!)我們認爲值得你全神貫注。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想看看另一家公司——一家財務狀況可能優越的公司——那麼千萬不要錯過這份免費的股本回報率高、債務低的有趣公司的名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論